{
  "docId": "019de070-19a4-704e-b5bc-b8f4ae0c7550",
  "docSlug": "2cfade3d34acc49c8d5f05063b654956",
  "documentTitle": "ATAI | Investor Presentation Deck | 49 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2020-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 49,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide uses a vertical process flow to map development stages to key de-risking milestones.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-19a4-704e-b5bc-b8f4ae0c7550/19",
  "deckHref": "/decks/019de070-19a4-704e-b5bc-b8f4ae0c7550",
  "deckJsonHref": "/decks/019de070-19a4-704e-b5bc-b8f4ae0c7550.json",
  "deckAnchorHref": "/decks/019de070-19a4-704e-b5bc-b8f4ae0c7550#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.18,
        "x": 0.46,
        "y": 0.22
      },
      "kind": "diagram",
      "text": "Development stages from In Vitro to Phase 2a, CIAS",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c5c5e31d-8a62-45af-8361-c2db4d117c2b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.25,
        "x": 0.68,
        "y": 0.22
      },
      "kind": "list",
      "text": "Consistent PK-PD relationship; Confidence in active dose range; Complete CMC package; Excellent tolerability and safety; Multiple clinical cognitive signals; De-risked path forward",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "605091c3-4021-4934-b274-0de59257fff8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.4,
        "x": 0.06,
        "y": 0.22
      },
      "kind": "list",
      "text": "1. Pharma developed product in-licensed with extensive pre-clinical & clinical data package. 2. Human Phase 1 + 2 data show replicated, clinically significant learning and memory effects. 3. Well tolerated (>500 subjects dosed). 4. Initial indication: CIAS.",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "36c45938-2a0a-40b4-9e2e-edf454af9442",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.85,
        "x": 0.05,
        "y": 0.07
      },
      "kind": "title",
      "text": "RL-007: a de-risked pro-cognitive neuromodulator with excellent tolerability in humans",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "03bbca3f-811c-4236-b7fc-14264cb9ed19",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "c90a7c69-a997-4dd4-8e82-4d8bcca2722e",
      "evidence": "Vertical flow of development stages",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}